The biological potential of teratoma remains unpredictable, therefore identifying its presence in the retroperitoneum remains important. We evaluated patients undergoing post-chemothe rapy retroperitoneal lymphadenectomy (PC-RPLA) for nonseminomatous testicular tumors (NSTT), to determine predictors of teratomatous elements in the retroperitoneum. We identified 161 patients from 1982 to 2005 who underwent PC-RPLA for metastatic NSTT. Multiple clinical and pathological variables were reviewed from out RPLA database. Of the 161 patients in our series, 112 (70%) received only induction chemotherapy and 49 (30%) required 2nd line chemotherapy. Studies of retroperitoneal pathology demonstrated the presence of fibrosis in 44 (27%), teratoma in 82 (51%) and vital carcinoma in 35(22%).Among 82 patients (51%) with finding of teratomatous elements at PC-RPLA, we revealed the presence ofmature teratoma in 85%, immature teratoma in 12% and teratoma with malignant transformation in 3%. Of the 99 patients (61%) with teratomatous elements in the primary NSTT, 61 (62%) had teratoma at PC-RPLA. Even in the absence of teratoma in the primary NSTT, teratoma was present in the retroperitoneum in 21 of 62 patients (32%)(p<0.0001). All patients had normal values of serum tumor markers (STM) at PC-RPLA. Post-chemotherapy retroperitoneal residual mass measuring <2 cm, from 2.1-5.0 cm and > 5 cm in diameter occured in 30%, 52% and 55%, respectively. By multivariate analysis , teratoma in the orchiectomy specimen (p<0.005), relative change in nodal size before and after chemotherapy (p<0.005), and no requirement for 2nd line chemotherapy (p=0.33) were independent predictors for the presence of the teratoma in the retroperitoneum. Teratoma remains a common histologic finding in the retroperitoneal lymph nodes following chemotherapy. We have identified several pre-RPLA variables that predict the finding of teratoma in the retroperitoneum for men treated with chemotherapy for metastatic NSTT.
Sheinfeld J, Herr H. Role of surgery in management of germ cell tumors. Semin Oncol. 1998;203–9.
2.
Dj A, Argirović A. Pathologic findings and clinical outcome in patients undergoing retroperitoneallymphadenectomy after multiple chemotherapy regimens for metastatic non-seminomatous testicular tumors. Materia Medica. 2011;(195):202.
3.
Argirovic D, Stanic V, Argirovic A. Recurrences in nonseminomatous testicular tumors with no viable cancer at postchemotherapy retroperitoneal lymphadenectomy. Eur Urol. 2010;237.
4.
Argirovic D, Argirovic A, Stanic V. The impact of extra-retroperitoneal masses in patients with advanced nonseminomatous testicular tumors. Eur Urol. 2010;239.
5.
Toner G, Panicek D, Heelan R, Geller N, Lin S, Bajorin D. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendationfor patients selection. J Clin Oncol. 1990;1683–94.
6.
Steyeberg E, Keizer H, Fossa S, Slejfer D, Toner G, Kopps S, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumors: multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995;1177–87.
7.
Dj A, Argirović A. Pure testicular teratoma in adults: experience in the treatment of 49 conssecutive cases. Materia Medica. 2011;221–7.
8.
Argirovic D, Argirovic A. Long term outcome after postchemotherapy retroperitoneal lymphadenectomy in patients with residual teratoma. Eur Urol. 2010;236.
9.
Argirovic D, Argirovic A. Teratoma indentified after postchemotherapy retroperitoneal lymphadenectomy. Materia Medica. 2013;889–97.
10.
Argirovic D. Late relapses of germ cell tumors following treatment for nonseminomatous testicular tumors according to single center-based experience. Eur Urol. 2007;539.
11.
Fossa S, Quist H, Stenwig A, Lien H, Ous S, Giercksky K. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol. 1992;569–73.
12.
Fossa S, Ous S, Lien H, Stenwig A. Postchemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol. 1989;575–9.
13.
Argirovic D, Argirovic A. Long term follow-up of cisplatin combination chemotherapy in patients with disseminated non-seminomatous testicular tumors: is a post-chemotherapy retroperitoneal lymphadenctomy needed after complete remission? Eur Urol. 2011;319.
14.
Schmoll H, Sonchon R, Krege S, Albers P, Beger J, Kollmannsberger C. European Concensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Concensus Group (EG CCCG). Ann Oncol. 2004;1377–99.
15.
Motzer R, Amsterdam A, Prieto V, Scheinfeld J, Murty V, Mazumdar M. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol. 1998;133–8.
16.
Baniel J, Foster R, Gonin R. Late relapses of testicular cncer. J Clin Oncol. 1995;1170–6.
17.
Dieckmann K, Albers P, Classen J, Witt D, Pichlmeir M, Rick U, et al. Late relapses of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol. 2005;824–9.
18.
Debono D, Heilman D, Einhorn Lh, Donohue J. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol. 1997;1455–64.
19.
Rabbani F, Gleare M, Chopin C, Murray N, Sullivan L. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements. Cancer. 1996;480–6.
20.
Beck S, Foster R, Bihrle R, Ulbright T, Koch M, Wahle G. Teratoma in the orchietomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol. 2002;1402–4.
21.
Donohue J, Rowland R, Kopecky K, Steidle C, Geier G, Ney K. Correlation of computerized tomography changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol. 1987;1176–9.
22.
Pfister D, Busch J, Schrader M, Winter C, Albers P, Dieckmann K. Pathohistological findings in patients with nonseminomatous germ cell tumours who undergo post-chemotherapy retroperitoneal lymph node dissection for small tumors. Eur Urol Supp. 2011;319.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
